Slingshot Biosciences raises $23M for synthetic cell platform

By The Science Advisory Board staff writers

July 23, 2021 -- Slingshot Biosciences announced the closing of $23 million in series A financing to fund the company's synthetic cell products portfolio.

As part of the funding, Adam Wieschhaus, PhD, director at Northpond Ventures, and Corey Ritter, senior associate at Arch Venture Partners, will join Slingshot's board of directors. Both companies took part in leading the investment initiative.

Slingshot will also invest in its broader adoptive cell therapy and therapeutics platform with this growth financing, the company said. The company is aiming its technology at adoptive cell therapy tools and therapeutic modalities that can use its synthetic cell engineering platform.

Copyright © 2021

BioTech Pharma Summit
September 27-28
Porto Portugal
Infectious Diseases (ID) Week 2021
September 29 - October 3
San Diego, California United States
Imaging Mass Spectrometry Society (IMSS) 3 in 2021
October 3-6
Colorado Springs, Colorado United States
Cell & Gene Meeting on the Mesa
October 10-14
Carlsbad, California United States
Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter